Primary Immunodeficiency Disease News

BOSTON — Genetic testing can play a positive role and help improve outcomes in managing immunodeficiencies, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients with primary immunodeficiencies experience an average of 9 to 15 years between the onset of their symptoms to diagnosis of their disorder and treatment that could save their lives, according to the Immune Deficiency Foundation.

Dupilumab was safe and effective in treating a group of six children and young adults with inborn errors of immunity and moderate to severe atopic dermatitis, according to a study published in Pediatric Allergy and Immunology.

Patients infected with SARS-CoV-2 saw a reduction of immune cells and a change in growth factor patterns in their blood 10 months after infection, according to a study published in Allergy.

Patients infected with SARS-CoV-2 showed signs of reduced immune cells and a change in growth factor patterns in their blood 10 months after infection, according to a study published in Allergy.

There are more than 450 monogenetic immune deficiencies. While many of these rare conditions have similar hallmarks, it is crucial for clinicians to differentiate between them.

Healio compiled the most-read news in allergy, asthma and immunology posted in May.

Healio has compiled April’s most-read news in asthma and allergy.

The FDA has approved mavorixafor for treating warts, hypogammaglobulinemia, infections and myelokathexis — or WHIM — syndrome, a rare and chronic primary immunodeficiency, according to a press release from X4 Pharmaceuticals.